
Dr. Ghosh on the Impact of Ide-Cel in Relapsed/Refractory Multiple Myeloma
Monalisa Ghosh, MD, discusses the impact of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Monalisa Ghosh, MD, a clinical assistant professor at the University of Michigan, discusses the impact of idecabtagene vicleucel (Abecma) in patients with relapsed/refractory multiple myeloma.
The agent was
The trial was important, as it took a population of patients without many treatment options and provided a new promising prospect for therapy, Ghosh concludes.



































